Background: Limited guidance exists for selecting a laboratory method for diagnosing GH deficiency (GHD) when it occurs as a late effect of radiotherapy in childhood cancer survivors (CCSs).
C linical manifestations of GH deficiency (GHD) vary by age and pubertal stage and can be nonspecific, and a GHD diagnosis must be confirmed via appropriate laboratory evaluation. However, hormonal testing remains imprecise, with highly variable accuracy. Low serum levels of IGF-1 or IGF-binding protein 3 (IGFBP-3) appear to suggest the diagnosis in adults and can be used to diagnose GHD in children with structural abnormalities, known hypopituitarism, or underlying genetic causes (1) . However, normal IGF-1 levels do not exclude the diagnosis and thus mandate further investigation.
Because of the pulsatile secretion of GH, multiple sampling is not practical in the clinical setting; dynamic hormonal testing remains the primary modality used to diagnose GHD. The insulin tolerance test (ITT) has been long considered the gold standard test to diagnose GHD in adults; however, its use has been limited because of the associated risks, mainly hypoglycemia and seizures. GH stimulation testing with a multitude of other agents has been evaluated in this setting. However, these tests have significant intrinsic false-positive rates. Recent observational data revealed that the levodopa/arginine combination and glucagon stimulation testing are the most widely used in the United States (27% and 25%, respectively) (2) . The combination of GHRH and arginine stimulation provided 95% sensitivity and 91% specificity compared with the ITT in the general population. The four other stimulation tests using arginine alone, clonidine, levodopa, and arginine plus levodopa in combination did not perform as well (3) .
Because of the advances in care for childhood malignancies, an estimated 0.2% of US adults in their second or third decade of life are childhood cancer survivors (CCSs) (4) . Improved survival rates have increased the recognition of late-onset complications related to cancer treatments, especially radiotherapy, commonly referred to as late effects. The lifetime prevalence of endocrine late effects in CCSs has been estimated at 50% (5) . Hypothalamic/pituitary (HP) irradiation is the primary risk factor for GHD, with a reported prevalence of 46.5% in CCSs treated with this modality (5) .
Although GHD is the most common, and often only, endocrine late effect experienced by CCSs exposed to HP radiotherapy, data pertaining to laboratory testing modalities for GHD in this population are scarce and provide only limited guidance. Most of the literature on GHD diagnosis is derived from people who were not CCSs despite suspected differences due to the location and nature of radiation-induced damage (6) . Therefore, an Endocrine Society taskforce was charged to develop guidance on the management of HP and growth disorders in CCSs. To support this guideline, we systematically reviewed the available evidence for GHD diagnostic testing in CCSs after HP radiation. We specifically aimed to evaluate the utility of IGF-1 and IGFBP-3 in this population and the relative significances of the various dynamic GH testing methods.
Methods
We performed a systematic review of evaluating screening for GHD by using IGF-1 or IGFBP-3 measurements compared with GH dynamic testing and diagnosing GHD by using various GH dynamic tests. The approach of this systematic review followed standards set by the Cochrane Collaboration and are reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (7).
Eligibility criteria
We searched for cohort studies and case series evaluating the diagnostic accuracy of provocative, dynamic, and static testing when compared with reference standard tests. We included studies reporting .10 patients undergoing any kind of GH testing.
Study identification
A comprehensive search of several databases was conducted from each database's inception to 1 March 2016 in any language.
The databases included Ovid Medline In-Process & Other NonIndexed Citations, Ovid Medline, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by a medical reference librarian with input from the investigators. Controlled vocabulary supplemented with keywords was used to search for studies on GHD diagnosis in CCSs.
Subsequently, references for the studies included in the original search were screened by the reviewers for further inclusions. Finally, additional references were obtained directly from the Endocrine Society taskforce members.
Selection of studies
Reviewers working independently and in duplicate reviewed all the retrieved abstracts and selected full-text manuscripts for eligibility. Disagreements regarding the full-text screening were resolved by the consensus of two reviewers.
Data collection and management
Working independently and in duplicate, reviewers used a standardized Web-based form to collect information from each eligible study. We recorded the age and sex of the included population, the GHD testing methods, and the cutoffs used for detection and diagnosis. The outcome of interest was the performances of the various GH testing methods against each study's gold standard.
Risk of bias and quality of evidence
Reviewers working independently and in duplicate used the Quality Assessment of Diagnostic Accuracy Studies 2 tool to assess the risk of bias for each study included (8) . The quality of evidence was evaluated via the Grades of Recommendation, Assessment, Development and Evaluation approach (9) .
Results

Search results
A total of 211 citations were retrieved. After abstract review, 177 full-text studies were reviewed for a final inclusion of 15 studies. Figure 1 summarizes the flow of the study selection and exclusion criteria. Table 1 shows detailed characteristics of the included patients. Overall, 477 patients, including children, adolescents, and young adults with a male preponderance (n = 266, 56%), were evaluated in 15 studies. Notably, 5 studies did not report the age at diagnosis, and 3 did not report the age at the time of GHD evaluation; thus, a median age for the entire population could not be accurately estimated. In addition, 2 studies did not report the sex proportions of their cohorts.
Patient characteristics
The most common childhood cancers were acute lymphoblastic leukemia (ALL) (n = 177) and medulloblastoma (n = 90). All patients received HP, cranial, or craniospinal radiation. Some studies enrolled healthy controls and performed the same index testing in both groups. The latter group of studies did not appropriately evaluate the performances of the index tests because they lacked a reference diagnostic test.
Study characteristics
Arginine stimulation and the ITT were used in 9 studies each, mostly as comparator tests. Two studies combined GHRH with arginine. GHRH stimulation was used in isolation in 4 other studies, one of which used a formulation of human pancreatic GH-releasing factor (hpGRF1). Finally, one study evaluated GH secretion after exercise. Nonprovocative tests included IGF-1 in 10 studies, IGFBP-3 in 9 studies, and continuous GH profiles in 3 studies (24-hour profiling in 2 and nocturnal sampling in 1). The individual study characteristics are listed in Table 2 .
There was high variability in the confirmatory test performed in each study and in the testing strategies. The major analytical challenge was the lack of a gold standard to diagnose GHD. A number of studies used the ITT as a reference, and other studies compared the performance of multiple tests against each other.
Provocative tests
GH provocative test protocols
Insulin. After an overnight fast, insulin was injected intravenously at a dosage of 0.07-to 0.2 U/kg body weight, and hypoglycemia was subsequently confirmed after serial glucose measurements, with nadir glucose levels reported between 30 and 50 mg/dL. Blood was drawn at 18-to 30-minute intervals after the injection for a duration of 90 to 120 minutes for GH measurements (6, (10) (11) (12) (13) (14) (15) (16) . Lisset et al. (17) reported the achievement of "satisfactory hypoglycemia" but no time intervals or durations of the blood draws.
GHRH. Human recombinant GHRH was administered intravenously at a dosage of 1 mg/kg after an overnight fast, and GH measurements were taken every 15 to 30 minutes for a duration of 60 to 120 minutes (6, 15, 16, 18, 19) . Only one study reported a maximal dosage of 50 mg (15).
Arginine. Arginine used in isolation or in combination with GHRH was administered at a dosage of either 20 g/m 2 or 0.5 g/kg via intravenous infusion over 30 minutes, and subsequent GH measurements were taken every 15 to 30 minutes. When used in combination with GHRH, the infusion was started immediately after GHRH administration, and the duration varied from 60 to 120 minutes (6, 10, 12, 16, 17) . Only one study reported a maximal dosage of 30 g.
Levodopa. GH measurements after the oral administration of levodopa at 290 mg/m 2 body surface area were performed every 30 minutes for durations of 90 to 120 minutes (20, 21) . One study did not report dosing, intervals, or follow-up duration (22) .
Clonidine. Clonidine was administered at a dosage of either 150 mg/m 2 or 0.1 mg orally once, and GH was measured every 30 minutes for a duration of 120 minutes (21, 22) . Tillmann et al. (14) did not report their stimulation testing strategies.
GH assays
Although most studies used the double antibody RIA technique for the measurement of GH (10-13, 15, 17-19, 21, 22) , three studies used a dissociation-enhanced lanthanide fluorescence immunoassay instead (16, 20, 21) . However, all assays used international standard preparations as references (International Reference Preparation 66/217 before 1990 and World Health Organization 80/505 after 1990).
Cutoff values
The various cutoff values used by the studies evaluated ranged from 4.67 mg/L to 10 mg/L and are summarized in Table 2 . The GH values have been converted to a single unit of mg/L for better comparison.
Performance
Because of the lack of a single comparator used in all or most of the studies, meta-analyses of sensitivity and specificity could not be performed for the index tests. Despite high variability in the testing protocols, dynamic tests remained the most accurate in appropriately identifying patients with GHD, and the ITT was the most commonly used reference test. The ability of GHRH stimulation, with or without arginine, to diagnose GHD across different studies was equivocal; in one study, GHRH in combination with arginine stimulation was 66% sensitive and 88% specific in comparison with the ITT (16).
IGF-1 and IGFBP-3
Overall, IGF-1 and IGFBP-3 had poor diagnostic accuracy (6, 14) . When calculations were possible, the sensitivity and specificity of IGF-1 varied from 47% to 66% and 77% to 100%, respectively (14, 22) . IGFBP-3 had a low sensitivity of 20%. However, most studies showed a strong correlation between IGF-1 and IGFBP-3 (13, (19) (20) (21) (22) (23) . The use of simultaneous testing in the same cohort did not increase the diagnostic accuracy of either test alone (20) .
GH secretion profiles
Insufficient data were available to assess the accuracy of serial blood sampling (collected both nocturnally and over a 24-hour period) for the determination of GH.
Risk of bias (methodological quality) and quality of evidence
The methodological quality of the included studies was moderate overall. However, the cohorts could not be combined, and the index tests could not be compared given the high interstudy variability in the testing strategies, cutoff levels, and, most importantly, comparator tests. The quality of evidence (certainty in diagnostic estimates) was moderate because of the small sample size and inability to aggregate data.
Discussion
Although a rare disorder (estimated prevalence of 1 in 4000 adults), GHD is the most common endocrinopathy in survivors of childhood central nervous system tumors and in those exposed to HP radiation. The latter includes survivors of childhood ALL exposed to prophylactic or therapeutic central nervous system radiotherapy, patients receiving conditioning total body irradiation (TBI) before stem cell transplantation, and patients with non-HP intracranial solid tumors, such as nasopharyngeal carcinoma and retinoblastoma. The availability of recombinant human GH and its beneficial effects on adult height prospects highlight the importance of diagnosing GHD in these patients. Minimizing false-positive tests for GHD is also important given the safety concerns surrounding the use of GH in CCSs due to its known promitogenic and proliferative properties in vitro (5, 24) .
The risk of GHD increases in a time-dependent fashion in relation to radiotherapy, and its prevalence thus increases with longer follow-up durations. GHD is also radiation dose-dependent, with the highest risk after HP radiation with $30 Gy; however, risks also occur after 18 to 30 Gy, after TBI with $10 Gy in one fraction, and after TBI with $12 Gy in multiple fractions. Additional risk factors include HP tumor involvement, young age at diagnosis, and use of tyrosine kinase inhibitors or anti-CTLA4 monoclonal antibodies (5, 25) . In fact, the increasing use of immune checkpoint inhibitors to treat malignancies such as malignant melanoma has shed light on the increased incidence of immune-mediated endocrine disorders, such as hypophysitis, thyroiditis, and autoimmune diabetes mellitus.
GHD diagnosis in both adult and pediatric general populations is challenging, mostly because of the lack of standardization of diagnostic tests, their respective cutoff values, and assay variability. Similarly, a consensus on the optimal testing method to diagnose GHD in CCSs is lacking. GHD typically presents with a decreased growth velocity compared with sex-and age-adjusted reference values (less than 22 SD over 1 year or 21.5 SD over 2 years). However, confirmatory testing is essential but requires a good understanding of the technical considerations and challenges of these tests.
GH provocative tests
GH stimulation tests aim to demonstrate inappropriately low peak levels of GH after physical or chemical stimulation. Physical stimulation has long been eliminated from routine use because of its lack of precision. Pharmacological stimulation uses GHRH, arginine, clonidine, glucagon, insulin, or levodopa. Kirk et al. (12) used exercise stimulation in parallel with other provocative tests, but this study is listed in our evaluation for completeness. Similarly, a study by Ahmed et al. (11) is included despite its lacking the modern use of hpGRF1 stimulation.
The ITT has traditionally been used as the gold standard, and most index tests evaluated were compared with some version of the ITT. GHRH stimulation, with or without arginine, had substantial clinical use before November 2008, when it became no longer commercially available in the United States. Glucagon stimulation has since increased in popularity for use in patients with contraindications to the ITT but was used in only one CCS study.
Provocative test protocols
Overall, homogeneity was observed regarding the protocols used to stimulate GH responses in dynamic tests, which was most notable in terms of dosing regimens and administration route. Differences were related mostly to the time of follow-up to detect peak GH responses, varying from 60 to 180 minutes. There were also some differences in the blood sampling intervals, which varied from 15 to 30 minutes. Notably, two studies measured the baseline GH twice, both at 15 to 30 minutes before the initiation of dynamic testing and at the start of the test, whereas all other protocols used only the measurement at time zero.
Sex steroid priming
The current guidelines for GHD testing in children and adolescents recommend priming prepubertal children of pubertal age with sex steroids before provocative GH testing to better differentiate GHD from constitutional delay (26); this recommendation is based largely on observational data in boys. There has been no evaluation of sex steroid priming in CCSs, a population that is enriched for delayed puberty due to hypogonadotropic hypogonadism and primary gonadal insufficiency, and none of the studies evaluated used such a protocol before GH stimulation.
GH assays
A multitude of test methods are currently used for GH measurement. Interassay variability was reported at 25% in an audit of 96 UK clinical laboratories. In Germany, a comparative study determined that a GHD diagnosis depends on the assay used in~30% of children undergoing GH stimulation. Most of this variability results from the presence of multiple GH variants in serum, including polymeric and fragmented forms, which are differentially detected in various assays (24) . As with all hormones, protein-bound and free forms of GH can also affect testing results. Mass spectrometry has been suggested to overcome a proportion of this variability, but the most recent consensus statements and guidelines highlight the importance of using a single reference material across laboratories to harmonize GH measurements (27) .
The studies we evaluated spanned three decades. During this time, shifts from polyclonal to monoclonal antibody use in the RIA and from purified human GH reference solutions to recombinant solutions occurred, leading to higher specificity in the currently used assays. These differences affect the comparative interpretations of the tests and the cutoffs used for diagnosis, although they do not influence the evaluation of individual tests in individual studies.
Cutoff levels
Controversies remain regarding the optimal GH cutoff levels for GHD diagnosis via a specific provocative test and the point at which GH replacement is indicated. Historically, a cutoff value of 5 mg/L correlated with GHD phenotypes, particularly pertaining to height velocity and adult height (24) . Allowing for assay differences, including the introduction of mass spectrometry, a recent study from Germany ascertained a total GH of 7 mg/L as the diagnostic cutoff. A 2016 survey of 48 pediatric departments and 57 biochemistry departments in the UK found that the cutoff values used to diagnose GHD in children ranged from 5 to 10 mg/L, with the overwhelming majority using a cutoff of ,7 mg/L (28). A similar pattern was seen in our review of published studies on CCSs.
Response to GH stimulation is also affected by body mass index, as determined by blunted responses in obese and overweight patients. In adults, this difference is reflected by the reliance on IGF-1 for diagnosis. Multiple provocative studies in children use differential cutoffs based on body weight or body mass index, but none of these studies include CCSs. Thus, using similar adjustments in this population could be accomplished only by extrapolation and would not account for the overall metabolic effects of HP dysfunction as opposed to isolated GHD or GHD due to other etiologies. Furthermore, GHD due to hypothalamic dysfunction can be missed by provocative testing that includes GHRH stimulation, because these patients can have false-negative responses, particularly early in the disease process.
Test performance
In addition to the aforementioned assay variability and test interpretations, the lack of a reference comparative test has led to variability in the reported reproducibilities and accuracies of the various provocative tests. The ITT has largely been considered the gold standard, and other provocative tests are recommended only when contraindications to the ITT occur (i.e., seizure disorders and cardiovascular disease). The false-positive rates of the various dynamic tests range from 8.9% to 49% (29) . False-negatives are also common, with glucagon stimulation testing being reported to miss #58% of patients with GHD diagnosed based on both the ITT and arginine stimulation tests (30) .
Based on data gathered from our evaluation of various studies, the diagnostic accuracy patterns of all the index tests appear to mimic those seen in the general population. Arginine used in isolation has had poor reproducibility, with up to two-thirds of patients having different diagnostic outcomes upon retesting with the same stimulation test (31) . In the general population, both the same test in the same child and two different tests in the same child have poor reproducibility. Retrospectively, in a large French cohort study, the ITT was the only test whose confidence interval, albeit very wide, crossed the satisfactory threshold value when performed in duplicate (32) . None of the provocative tests evaluated in our report were tested for reproducibility over time.
GH secretion profiles
Pituitary GH secretion is pulsatile, with most pulses occurring overnight and thus limiting the utility of random GH sampling. Obtaining 12-or 24-hour GH profiles has previously been used but has very limited clinical use today given the frequent sampling necessary and the need for hospital admission. Furthermore, both the sensitivity and specificity of this protocol have been questioned, because overlap in secretory profiles occurs between healthy individuals and those with GHD (33, 34) .
IGF-1 and IGFBP-3
Under the control of GH, the liver produces circulating IGF-1 bound to numerous binding proteins, including IGFBP-3. Both IGF-1 and IGFBP-3 exist in a steady state at constant concentrations and thus offer the advantage of random serum sampling for measurement. However, normative values need to be adjusted not only for chronological age but also for pubertal age and Tanner stage. Similar to GH, assay variability and standardization problems also exist for World Health Organization solutions (27) . In the general population, IGF-1 is known to have a high specificity (#95%); however, a normal level does not exclude GHD but rather warrants additional testing based on clinical suspicion. IGFBP-3 performance has been similar and does not add value to the IGF-1 measurement (35) . In CCSs, however, the use of either of these markers does not appear promising, because their diagnostic accuracies are quite poor even when used in combination.
Diagnosis
The availability of recombinant GH treatment has made establishing a diagnosis crucial to appropriately identifying patients who would benefit from such therapy. Given the lack of strong evidence supporting treatment in patients with isolated GHD or idiopathic short stature, guidelines have recommended the use of two provocative tests to establish the diagnosis in children. However, CCSs have established cranial pathologies or have been subjected to HP radiation and thus need a lower testing threshold based on these guidelines. Subsequently, a failure to stimulate GH in any one provocative test is sufficient to establish the diagnosis due to high pretest diagnostic suspicion, especially in the presence of other HP deficits, with the caveat that a poor growth rate may be caused by skeletal growth impairment independent of GHD after treatment with agents such as TBI, imatinib mesylate, and cis-retinoic acid (36) (37) (38) (39) (40) .
This caveat highlights the importance of testing reproducibility and accuracy in this population. The ITT, GHRH (with or without arginine), and glucagon have been recommended by the Endocrine Society, in this order, for the diagnosis of GHD in adults. In CCSs, however, the use of GHRH is not recommended for the reasons discussed earlier. Glucagon stimulation has not been investigated enough in this population, and the ITT thus remains the only reliable dynamic test even though its performance is based largely on the general population and historical experience.
Finally, reliance on nonprovocative tests in this population is not recommended. GH profiling has been replaced by less labor-intensive and more cost-efficient testing; IGF-1 and IGFBP-3 performed poorly in this population, in contrast to the general pediatric and adult populations tested for GHD, and thus cannot be used to establish diagnosis.
Limitations
The studies included in this report span four decades and represent an array of testing and clinical consensuses, which has led to variability in reporting results and outcomes. Thus, calculating the diagnostic accuracies of the various tests evaluated based on the available primary data was not possible. Additionally, there is no gold standard for diagnosing GHD to which to compare any of these tests.
Conclusion
Evaluating the GH axis in CCSs is an opportunity to treat these patients with available and effective replacement therapy. The controversy regarding the benefit-to-risk ratios of such therapies highlights the importance of appropriate patient selection and accuracy of testing for GHD. Based on this systematic review, dynamic testing remains the cornerstone for GHD diagnosis. Additional research on this population is needed to establish the best possible test. In the meantime, however, reliance on the ITT (as the gold standard) appears to be appropriate, with recognition that this test is not feasible at many institutions.
